| SAN DIEGO, May 2, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV) announced today that the Company has initiated development of a diagnostic test to determine the presence of high risk Human Papilloma Virus (HPV) subtypes from urine specimens. The proprietary test (U.S. patent application pending) might, once available, be particularly useful for the determination of carrier status in males. The Company's HPV detection assay is a unique, proprietary(1) method that preferentially amplif...continued TROV |
SmallCapUpdates provides the latest news and alerts on stocks for you. If you are looking for the latest on stocks in clean energy, medical innovation, mining, biotech, nanotech, renewable energy, internet technology or in emerging markets.
Pages
▼
No comments:
Post a Comment